Browse by Hotbed/Location
Filter News
Found 663,636 articles
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Danaher Schedules Third Quarter 2021 Earnings Conference Call
9/21/2021
Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2021 on Thursday, October 21, 2021 beginning at 8:00 a.m. ET and lasting approximately 1 hour.
-
Imugene and City of Hope announced that the first patient has begun treatment in a Phase I clinical trial, investigating the safety and efficacy of CF33-hNIS in adults with metastatic or advanced tumors.
-
Caladrius Biosciences announced it was suspending enrollment in its Phase IIb FREEDOM study assessing xowna for coronary microvascular dysfunction (CMD) due to supply chain issues.
-
Alnylam Pharmaceuticals announced Tuesday new positive results from the Phase III ILLUMINATE-C trial of lumasiran for advanced primary hyperoxaluria type 1 (PH1).
-
FDA Accepts CSL Behring's Biologics License Application for Etranacogene Dezaparvovec for Priority Review
5/24/2022
FDA Accepts CSL Behring's Biologics License Application for Etranacogene Dezaparvovec for Priority Review.
-
Natera Appoints Minetta Liu, M.D. as Chief Medical Officer of Oncology
5/24/2022
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the appointment of Minetta Liu , M.D., as its new chief medical officer (CMO) of oncology.
-
Embleema and CDISC Partner to Develop Standards for Cell and Gene Therapy Product Monitoring
5/24/2022
Embleema Inc. and CDISC have announced a collaboration to develop new standards for experimental assays and bioinformatics protocols to facilitate monitoring the activity of Cell and Gene Therapy Products (CGTP).
-
ORMCO™ ANNOUNCES SOLE U.S. DISTRIBUTION OF IMPROVED ORTHOPULSE® GEN.2 DEVICE
5/24/2022
Ormco Corporation , a global leader and innovator of orthodontic products and solutions, announces sole U.S. Distribution of the improved OrthoPulse® Gen.2 medical device.
-
Senti Bio Secures Additional Financing from Leaps by Bayer and Provides Update on Proposed Business Combination with Dynamics Special Purpose Corp. (DYNS)
5/24/2022
Leaps by Bayer led Series B investment in Senti Bio in 2021; Additional Convertible Note financing expands committed capital to PIPE investment associated with previously announced Business Combination Agreement with DYNS.
-
Halozyme Completes Antares Pharma Acquisition
5/24/2022
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced the successful completion of its acquisition of Antares Pharma, Inc. (" Antares ").
-
Acutis Names Abdel Halim, PharmD, MSc, PhD, DABCC, FAACC as Chief Scientific Officer
5/24/2022
Acutis, a specialized clinical and biosciences company, announced Dr. Abdel Halim has joined as Chief Scientific Officer and Executive Vice President.
-
Iterative Scopes DDW Presentation Shows Accuracy of Automated Endoscopic Disease Scoring Model, With Potential to Accelerate IBD Clinical Trials
5/24/2022
Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, announced today that data presented at Digestive Disease Week (DDW) 2022 show that the company’s proprietary machine learning model accurately and consistently predicts scoring of endoscopic disease severity in ulcerative colitis (UC), a common type of inflammatory bowel disease (IBD).
-
Evecxia Therapeutics Announces Issuance of US Patent Covering EVX-101 for Depression and Other CNS Disorders
5/24/2022
EVX-101 is a clinical-stage drug candidate currently being developed as an adjunctive treatment for when first-line antidepressants alone are inadequate.
-
FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm
5/24/2022
FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm.
-
Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab
5/24/2022
Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab.
-
LUXA BIO Announces First Participant Dosed in Phase 1/2a Clinical Trial of Adult RPESC-RPE-4W for Dry Age-related Macular Degeneration
5/24/2022
Luxa Biotechnology (LuxaBio), a joint venture between Y2 Solution Co. Ltd, Seoul, South Korea and the Neural Stem Cell Institute (NSCI), Rensselaer, New York, today announced transplantation of the cell product RPESC-RPE-4W into the first participant with dry age-related macular degeneration (dry AMD) in its Phase 1/2a clinical trial (NCT04627428) being conducted at the University of Michigan Kellogg Eye Center.
-
Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes
5/24/2022
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating Diabetes."
-
PrecisionOS Partners with Siemens Healthineers for VR-based Surgical Training Development
5/24/2022
PrecisionOS ® is now offering immersive virtual reality (VR) training in partnership with Siemens Healthineers.